ProMIS Neurosciences (PMN) awards CSO 50,000 options vesting over 4 years

Q: How many ProMIS Neurosciences shares are covered by Neil Cashman’s option grant?

The option grant covers 50,000 underlying Common Shares of ProMIS Neurosciences. These options were awarded as equity compensation and give him the right, but not the obligation, to buy those shares at a preset exercise price.

Q: When do Neil Cashman’s ProMIS Neurosciences options expire?

The options granted to Neil Cashman expire on May 20, 2036 . He can only exercise them before that date, and they vest gradually over four years, subject to his continued service with the company through each vesting date.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

ProMIS Neurosciences Inc. reported that Chief Scientific Officer Neil Cashman received a grant of options to buy 50,000 Common Shares. These options have an exercise price of $10.77 per share and expire on May 20, 2036. The award was made at no cost to him and represents equity-based compensation rather than an open-market purchase or sale. According to a footnote, the options vest ratably over four years, contingent on his continued service with the company. Following this grant, he holds 50,000 options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Cashman Neil

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Option (right to buy)	50,000	$0.00	--

Holdings After Transaction: Option (right to buy) — 50,000 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Options granted: 50,000 options Exercise price: $10.77 per share Expiration date: May 20, 2036 +2 more

5 metrics

Options granted 50,000 options Grant to Chief Scientific Officer on May 20, 2026

Exercise price $10.77 per share Exercise price for 50,000 options

Expiration date May 20, 2036 Option term for CSO grant

Underlying shares 50,000 Common Shares Shares issuable upon option exercise

Post-grant derivative holdings 50,000 options Total derivative securities following transaction

Key Terms

Option (right to buy), Grant, award, or other acquisition, Common Shares, vest ratably over four years

4 terms

Option (right to buy) financial

"security_title: "Option (right to buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Common Shares financial

"underlying_security_title: "Common Shares""

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

vest ratably over four years financial

"The shares subject to this option shall vest ratably over four years"

Form 4 Insider Transactions: What Each Field Means →

05/22/2026 - 04:33 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cashman Neil

(Last)

(First)

(Middle)

C/O PROMIS NEUROSCIENCES INC.

SUITE 200, 1920 YONGE STREET

(Street)

TORONTO

M4S 3E2

(City)

(State)

(Zip)

ONTARIO, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
ProMIS Neurosciences Inc. [ PMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Option (right to buy)	$10.77	05/20/2026		A		50,000		⁽¹⁾	05/20/2036	Common Shares	50,000	$0	50,000	D

Explanation of Responses:

1. The shares subject to this option shall vest ratably over four years, subject to continued service to the Issuer through each vesting date.

	/s/ Max A. Milbury, Attorney in Fact for Neil Cashman	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did ProMIS Neurosciences (PMN) report for Neil Cashman?

Neil Cashman received a grant of options to acquire 50,000 Common Shares of ProMIS Neurosciences. The options are a compensation award, not an open-market trade, and give him the right to purchase shares at a fixed exercise price.

What is the exercise price of Neil Cashman’s new ProMIS Neurosciences options?

The options granted to Neil Cashman carry an exercise price of $10.77 per share. This means he can buy up to 50,000 Common Shares at that price regardless of future market levels, once the options vest over time.

How many ProMIS Neurosciences shares are covered by Neil Cashman’s option grant?

The option grant covers 50,000 underlying Common Shares of ProMIS Neurosciences. These options were awarded as equity compensation and give him the right, but not the obligation, to buy those shares at a preset exercise price.

When do Neil Cashman’s ProMIS Neurosciences options expire?

The options granted to Neil Cashman expire on May 20, 2036. He can only exercise them before that date, and they vest gradually over four years, subject to his continued service with the company through each vesting date.

How do Neil Cashman’s ProMIS Neurosciences options vest over time?

According to the filing footnote, the 50,000 options vest ratably over four years. Vesting is contingent on Neil Cashman’s continued service to ProMIS Neurosciences through each scheduled vesting date, aligning the award with long-term employment.

Did Neil Cashman buy or sell ProMIS Neurosciences shares in this Form 4?

This Form 4 reports a grant of options, not a market trade. Neil Cashman acquired derivative securities as a compensation award, with no reported open-market purchases or sales of ProMIS Neurosciences Common Shares in this particular filing.